Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

341 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder - recommendations from ECTRIMS and the EBMT.
Muraro PA, Mariottini A, Greco R, Burman J, Iacobaeus E, Inglese M, Snowden JA, Alexander T, Amato MP, Bø L, Boffa G, Ciccarelli O, Cohen JA, Derfuss T, Farge D, Freedman MS, Gaughan M, Heesen C, Kazmi M, Kirzigov K, Ljungman P, Mancardi G, Martin R, Mehra V, Moiola L, Saccardi R, Tintoré M, Stankoff B, Sharrack B; Attendees of the ECTRIMS Focused Workshop on HSCT. Muraro PA, et al. Among authors: heesen c. Nat Rev Neurol. 2025 Jan 15. doi: 10.1038/s41582-024-01050-x. Online ahead of print. Nat Rev Neurol. 2025. PMID: 39814869 Review.
Erratum to "Nurse-led immunotreatment DEcision Coaching In people with Multiple Sclerosis (DECIMS) - A cluster-randomised controlled trial and mixed methods process evaluation" [Patient Educ Couns 125 (2024) 108293].
Rahn AC, Peper J, Köpke S, Antony G, Liethmann K, Vettorazzi E, Heesen C; DECIMS study group. Rahn AC, et al. Among authors: heesen c. Patient Educ Couns. 2025 Jan;130:108363. doi: 10.1016/j.pec.2024.108363. Epub 2024 Nov 13. Patient Educ Couns. 2025. PMID: 39536521 Free article. No abstract available.
Successful generation of fully human, second generation, anti-CD19 CAR T cells for clinical use in patients with diverse autoimmune disorders.
Mougiakakos D, Sengupta R, Gold R, Schroers R, Haghikia A, Lorente M, Pendleton M, Register A, Heesen C, Kröger N, Schett G, Mackensen A, Podoll A, Gutman J, Furie R, Bayer R, Distler JHW, Dietrich S, Krönke G, Bullinger L, Walker K. Mougiakakos D, et al. Among authors: heesen c. Cytotherapy. 2025 Feb;27(2):236-246. doi: 10.1016/j.jcyt.2024.09.008. Epub 2024 Oct 5. Cytotherapy. 2025. PMID: 39530971 Free article.
Treatment effect modifiers of immunotherapies for relapsing-remitting multiple sclerosis-A systematic review and meta-analysis.
Heesen C, Röver C, Salem S, Heinz J, Chard D, Rio J, Fittipaldo AV, Lehnert T, Köpke S, Solari A, Sormani MP, Friede T, Rahn AC. Heesen C, et al. Mult Scler J Exp Transl Clin. 2024 Oct 24;10(4):20552173241274618. doi: 10.1177/20552173241274618. eCollection 2024 Oct-Dec. Mult Scler J Exp Transl Clin. 2024. PMID: 39493424 Free PMC article. Review.
Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials.
Montalban X, Vermersch P, Arnold DL, Bar-Or A, Cree BAC, Cross AH, Kubala Havrdova E, Kappos L, Stuve O, Wiendl H, Wolinsky JS, Dahlke F, Le Bolay C, Shen Loo L, Gopalakrishnan S, Hyvert Y, Javor A, Guehring H, Tenenbaum N, Tomic D; evolutionRMS investigators. Montalban X, et al. Lancet Neurol. 2024 Nov;23(11):1119-1132. doi: 10.1016/S1474-4422(24)00328-4. Epub 2024 Sep 19. Lancet Neurol. 2024. PMID: 39307151 Clinical Trial.
341 results